Cutaneous Lupus Erythematosus (CLE) Epidemiology Forecast

• CLE is a chronic autoimmune disease affecting the skin; while cutaneous manifestations are common in lupus, skin-limited cases represent a subset of the overall lupus population.

• In 2025, the total number of diagnosed cases of CLE was ~892,000 cases in the 7MM, which is anticipated to increase during the forecast period (2026–2036).

• CLE encompasses a range of autoimmune skin disorders that can occur independently or in conjunction with systemic lupus erythematosus (SLE), affecting the skin with varying levels of systemic involvement.

• CLE affects all age groups, but is rare in children and is more common in females, with different proportions according to subtype. 

• The pathogenesis of CLE is multifactorial, with an interplay between genetic and environmental factors. Some contributing environmental factors include ultraviolet radiation (UVR), medications, cigarette smoking, and possibly viruses.

• The clinical manifestations and prognosis differ between the different categories of CLE. Almost 100% of patients with acute CLE progress to systemic disease, compared with only 5% of patients with chronic CLE and 30% of patients with subcutaneous CLE. Patients with generalized discoid lupus erythematosus are at a higher risk of progressing to systemic disease than those with a localized variant. Overall, approximately 25% of all patients with CLE progress to systemic disease.

Cutaneous Lupus Erythematosus (CLE) Epidemiology Forecast in the 7MM

• 2025 Diagnosed Prevalent Cases of Cutaneous Lupus Erythematosus (CLE): ~892,000

• Cutaneous Lupus Erythematosus (CLE) Growth Rate (2026–2036): 4% CAGR

DelveInsight's ‘Cutaneous Lupus Erythematosus (CLE) – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the CLE, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France), and the United Kingdom, and Japan.

Cutaneous Lupus Erythematosus (CLE) Understanding and Diagnosis Algorithm

Cutaneous Lupus Erythematosus (CLE) Overview

CLE is a complex inflammatory skin disorder that may occur independently or as a common manifestation of SLE. It comprises multiple subtypes with distinct clinical presentations and variable associations with systemic disease. Histologically, CLE is defined by interface dermatitis, characterized by immune cell infiltration at the dermoepidermal junction. Recent advances in the characterization of both lesional and non-lesional skin have significantly refined our understanding of disease pathogenesis. Notably, both exhibit early and sustained upregulation of type I interferons. This persistent interferon signaling contributes to photosensitivity, promotes recruitment of myeloid cells, and amplifies cytokine responses across both immune and resident skin cells.

Cutaneous Lupus Erythematosus (CLE) Diagnosis

Diagnosis of CLE is based on an integrated approach combining clinical evaluation, skin biopsy, and laboratory testing. Characteristic skin lesions and patient history guide initial assessment, while histopathological confirmation via biopsy remains the gold standard. Immunological tests, including ANA and other autoantibodies, help assess systemic involvement. Differential diagnosis is essential to exclude other dermatological conditions and ensure an accurate diagnosis.

Further details are provided in the report.

Cutaneous Lupus Erythematosus (CLE) Epidemiology

Key Findings from Cutaneous Lupus Erythematosus (CLE) Epidemiological Analysis and Forecast 

• The US accounted for approximately 60% of the total diagnosed prevalent cases of CLE in the 7MM in 2025. In the US, prevalence is estimated at 70–109 per 100,000, reflecting a sustained disease burden consistent with its chronic, relapsing nature.

• Chronic CLE is the most common subtype, accounting for approximately 70–80% of all CLE cases. Additionally, around 20–25% of patients with SLE may exhibit features of chronic cutaneous involvement.

• In 2025, among gender-specific cases of CLE in the US, females accounted for a significantly higher number of cases than males.

• The UK accounted for the highest diagnosed prevalence of CLE, representing 29% of cases across the EU4 and the UK, while Spain had the lowest diagnosed prevalence at approximately 14% of cases in 2025.

• In 2025, among type-specific CLE cases in Japan, Chronic CLE accounted for the highest proportion, followed by discoid lupus erythematosus.

Scope of the Cutaneous Lupus Erythematosus Market Report

• The report covers a segment of an executive summary, a descriptive overview of CLE, explaining its causes, signs, and symptoms, and pathogenesis.

• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Cutaneous Lupus Erythematosus Market Report Insights

• CLE Patient Population Forecast

Cutaneous Lupus Erythematosus Market Report Key Strengths

• Epidemiology‑based (epi‑based) Bottom‑up Forecasting

• 11-year Forecast 

• Patient Burden Trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of CLE? What will be the growth opportunities across the 7MM concerning the patient population with CLE?

• What is the historical and forecasted CLE patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy the Cutaneous Lupus Erythematosus Market Forecast Report

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

• To understand key opinion leaders’ perspectives on the diagnostic challenges to overcome barriers in the future.

• Detailed insights into various factors hampering disease diagnosis and other existing diagnostic challenges.